We also provided unique insight into haloperidol-promoted cell proliferation and tumor progression: haloperidol upregulates the NF-κB/CSF-1/CSF-1R signaling and engenders EC’s malignant transformation and progression; thereby, in vitro and in vivo blockage of CSF-1 or its receptor-ligand interaction reverses these haloperidol-promoted effects on EC. Here, NFKB1 is linked to neoplasm.